A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients

NCT00421512 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Renal Cell Carcinoma
Kidney Cancer

Interventions

DRUG: Bevacizumab and Sunitinib

Sponsor

Memorial Sloan Kettering Cancer Center